Please login to the form below

Not currently logged in
Email:
Password:

Pfizer may counter Daiichi's bid for Ranbaxy

Pfizer may be about to bid for a 65 per cent share of Indian generics company, Ranbaxy, according to a Business Standard report
Pfizer may be about to bid for a 65 per cent share of Indian generics company, Ranbaxy, according to a report in the Business Standard newspaper.

Ranbaxy, founded by the Singh family, has agreed a deal with Japan's Daiichi Sankyo, worth up to $4.6bn to take control of the company. However, it is rumoured that Pfizer, which held talks with Ranbaxy a year ago, may be about to make a counter bid.

According to the newspaper, a Ranbaxy spokesman said: "We have a binding contract with Daiichi. It is a final contract."

Pfizer has lost out to Ranbaxy in several international battles over the patent rights to Lipitor, its cholesterol drug. In most countries the patent will start expiring in 2011.

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics